GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Corp (FRA:PSH) » Definitions » Current Ratio

Sernova (FRA:PSH) Current Ratio

: 1.20 (As of Jan. 2024)
View and export this data going back to 2014. Start your Free Trial

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Sernova's current ratio for the quarter that ended in Jan. 2024 was 1.20.

Sernova has a current ratio of 1.20. It generally indicates good short-term financial strength.

The historical rank and industry rank for Sernova's Current Ratio or its related term are showing as below:

FRA:PSH' s Current Ratio Range Over the Past 10 Years
Min: 1.2   Med: 7.94   Max: 27.94
Current: 1.2

During the past 13 years, Sernova's highest Current Ratio was 27.94. The lowest was 1.20. And the median was 7.94.

FRA:PSH's Current Ratio is ranked worse than
80.18% of 1554 companies
in the Biotechnology industry
Industry Median: 3.795 vs FRA:PSH: 1.20

Sernova Current Ratio Historical Data

The historical data trend for Sernova's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Current Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.74 5.24 19.20 10.78 2.19

Sernova Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Current Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.20 6.28 3.23 2.19 1.20

Competitive Comparison

For the Biotechnology subindustry, Sernova's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sernova Current Ratio Distribution

For the Biotechnology industry and Healthcare sector, Sernova's Current Ratio distribution charts can be found below:

* The bar in red indicates where Sernova's Current Ratio falls into.



Sernova Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Sernova's Current Ratio for the fiscal year that ended in Oct. 2023 is calculated as

Current Ratio (A: Oct. 2023 )=Total Current Assets (A: Oct. 2023 )/Total Current Liabilities (A: Oct. 2023 )
=14.519/6.625
=2.19

Sernova's Current Ratio for the quarter that ended in Jan. 2024 is calculated as

Current Ratio (Q: Jan. 2024 )=Total Current Assets (Q: Jan. 2024 )/Total Current Liabilities (Q: Jan. 2024 )
=11.68/9.706
=1.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sernova  (FRA:PSH) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Sernova Current Ratio Related Terms

Thank you for viewing the detailed overview of Sernova's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sernova (FRA:PSH) Business Description

Traded in Other Exchanges
Address
700 Collip Circle, The Stiller Centre, Suite 114, London, ON, CAN, N6G 4X8
Sernova Corp is a clinical-stage company developing products for the treatment of chronic debilitating diseases. The company is engaged in the research and development of its proprietary Cell Pouch and associated technologies including immune-protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and or hormones for the long-term treatment of multiple serious, chronic diseases such as diabetes, hemophilia, and thyroid disease.

Sernova (FRA:PSH) Headlines